Noven Pharmaceuticals, Inc. announced that the new 0.025 mg/day dosage strength for Minivelle® (estradiol transdermal system) is now available by prescription nationwide for only the prevention of postmenopausal osteoporosis. The FDA initially approved Minivelle in October 2012 to treat moderate to severe vasomotor symptoms (VMS) due to menopause, commonly known as hot flashes. In September 2014, the FDA approved a new indication for prevention of postmenopausal osteoporosis for all doses of Minivelle. The new 0.025 mg/day low dose was approved for this indication only.
Happy Memorial Day
Today, we express our heartfelt gratitude to those who served and remember those who are no longer with us.
2 thoughts on “Minivelle® Available by Prescription Nationwide for Prevention of Postmenopausal Osteoporosis”
I’ve had breast cancer. Estrogen dominate Can I use something like this?
Jennes, I am not a doctor so I can’t answer this. I would definitely discuss your options with your menopause specialist. If you don’t have one, you can find some tips on how to find one in this Dear Ellen. Be sure to read my blog on Breast Cancer and Menopause. I interviewed two wonderful doctors from the Yale Cancer Center. I asked them the most common questions that women are asking me. They are the experts! I thought it was interesting that they recommend Remifemin as a non-hormonal option for natural symptom relief of hot flashes, night sweats & mood swings. It is estrogen free -made out of natural black cohosh. I hope this is helpful. Feel free to ping me back with any other questions you may have.